<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0015">
 <label>Table 3</label>
 <caption>
  <p>Ongoing clinical trials for COVID–19.</p>
 </caption>
 <alt-text id="al0030">Table 3</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>S. no.</th>
    <th>Study</th>
    <th>Drug</th>
    <th>Status</th>
    <th>Organization</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>1.</td>
    <td>Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19</td>
    <td>Sarilumab</td>
    <td>Recruiting</td>
    <td>Regeneron Study Site
     <break/>New York, New York, United States
    </td>
   </tr>
   <tr>
    <td>2.</td>
    <td>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</td>
    <td>Remdesivir</td>
    <td>Recruiting</td>
    <td>1. Hoag Memorial Hospital Presbyterian
     <break/>Newport Beach, California, United States
     <break/>2.Stanford Hospital, Stanford, California, United States
     <break/>3. Providence Regional Medical Center Everett, Everett, Washington, United States
    </td>
   </tr>
   <tr>
    <td>3.</td>
    <td>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</td>
    <td>Remdesivir</td>
    <td>Recruiting</td>
    <td>1. Hoag Memorial Hospital Presbyterian
     <break/>Newport Beach, California, United States
     <break/>2.Stanford Hospital, Stanford, California, United States
     <break/>3. Providence Regional Medical Center Everett, Everett, Washington, United States
    </td>
   </tr>
   <tr>
    <td>4.</td>
    <td>Fingolimod in COVID-19</td>
    <td>Fingolimod 0.5 mg</td>
    <td>Recruiting</td>
    <td>Wan-Jin Chen
     <break/>Fuzhou, China
    </td>
   </tr>
   <tr>
    <td>5.</td>
    <td>The Clinical Study of Carrimycin on Treatment Patients With COVID-19</td>
    <td>1.Carrimycin
     <break/>2. Lopinavir/ritonavir tablets or Arbidol or Chloroquine phosphate
    </td>
    <td>Not yet recruiting</td>
    <td>–</td>
   </tr>
   <tr>
    <td>6.</td>
    <td>Efficacy and Safety of Corticosteroids in COVID-19</td>
    <td>Methylprednisolone</td>
    <td>Recruiting</td>
    <td>1. Hubei province hospital of integrated Chinese &amp; Western Medicine
     <break/>Wuhan, Hubei, China
     <break/>2. Yichang first people's Hospital
     <break/>Yichang, Hubei, China
     <break/>3. Renmin Hospital of Wuhan University
     <break/>Wuhan, China
    </td>
   </tr>
   <tr>
    <td>7.</td>
    <td>Mild/Moderate 2019-nCoV Remdesivir RCT</td>
    <td>Remdesivir</td>
    <td>Recruiting</td>
    <td>Jin Yin-tan hospital
     <break/>Wu Han, Hubei, China
    </td>
   </tr>
   <tr>
    <td>8.</td>
    <td>Adaptive COVID-19 Treatment Trial</td>
    <td>Remdesivir</td>
    <td>Recruiting</td>
    <td>1.National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section
     <break/>Bethesda, Maryland, United States
     <break/>2. University of Nebraska Medical Center - Infectious Diseases
     <break/>Omaha, Nebraska, United States
     <break/>3. University of Texas Medical Branch - Division of Infectious Disease
     <break/>Galveston, Texas, United States
     <break/>4. Providence Sacred Heart Medical Center
     <break/>Spokane, Washington, United States
    </td>
   </tr>
   <tr>
    <td>9.</td>
    <td>Severe 2019-nCoV Remdesivir RCT</td>
    <td>Remdesivir</td>
    <td>Recruiting</td>
    <td>Bin Cao
     <break/>Beijing, Beijing, China
    </td>
   </tr>
   <tr>
    <td>10.</td>
    <td>Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.</td>
    <td>Nitric Oxide Gas</td>
    <td>Not yet recruiting</td>
    <td>–</td>
   </tr>
   <tr>
    <td>11.</td>
    <td>Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients</td>
    <td>Recombinant human interferon α1β</td>
    <td>Not yet recruiting</td>
    <td>–</td>
   </tr>
   <tr>
    <td>12.</td>
    <td>Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection</td>
    <td>1.ASC09/ritonavir group
     <break/>2. Lopinavir/ritonavir group
    </td>
    <td>Not yet recruiting</td>
    <td>–</td>
   </tr>
   <tr>
    <td>13.</td>
    <td>Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection</td>
    <td>mRNA-1273</td>
    <td>Not yet recruiting</td>
    <td>Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases
     <break/>Seattle, Washington, United States
    </td>
   </tr>
   <tr>
    <td>14.</td>
    <td>Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure</td>
    <td>Methylprednisolone</td>
    <td>Recruiting</td>
    <td>Medical ICU,Peking Union Medical College Hospital
     <break/>Beijing, Beijing, China
    </td>
   </tr>
   <tr>
    <td>15.</td>
    <td>Lopinavir/Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment</td>
    <td>1. Lopinavir/ritonavir
     <break/>2. Ribavirin
     <break/>3. Interferon Beta-1B
    </td>
    <td>Recruiting</td>
    <td>University of Hong Kong, Queen Mary Hospital
     <break/>Hong Kong, Hong Kong
    </td>
   </tr>
   <tr>
    <td>16.</td>
    <td>Efficacy of Chloroquine and Lopinavir/Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study</td>
    <td>1.Chloroquine
     <break/>2. Lopinavir/Ritonavir
    </td>
    <td>–</td>
    <td>The Fifth Affiliated Hospital Sun Yat-Sen University</td>
   </tr>
   <tr>
    <td>17.</td>
    <td>A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases</td>
    <td>Hydroxychloroquine</td>
    <td>–</td>
    <td>The Second Affiliated Hospital of Chongqing Medical University</td>
   </tr>
   <tr>
    <td>18.</td>
    <td>A prospective, randomized, open-label, parallel controlled trial for the preventive effect of hydroxychloroquine on medical personnel after exposure to COVID-19</td>
    <td>Hydroxychloroquine</td>
    <td>–</td>
    <td>Renmin Hospital of Wuhan University</td>
   </tr>
   <tr>
    <td>19.</td>
    <td>The efficacy and safety of carrimycin treatment in patients with novel coronavirus infectious disease (COVID-19): a multicenter, randomized, open- label controlled trial</td>
    <td>Carrimycin</td>
    <td>–</td>
    <td>Beijing You'an Hospital, Capital Medical University</td>
   </tr>
   <tr>
    <td>20.</td>
    <td>A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.</td>
    <td>recombinant human interferon alpha 1b</td>
    <td>–</td>
    <td>Chinese PLA General Hospital</td>
   </tr>
   <tr>
    <td>21.</td>
    <td>A Pilot Study of Sildenafil in COVID-19</td>
    <td>Sildenafil citrate</td>
    <td>Recruiting</td>
    <td>Department and Institute of Infectious Disease, Wuhan, Hubei, China</td>
   </tr>
   <tr>
    <td>22.</td>
    <td>Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</td>
    <td>
     <list list-type="simple" id="l0005">
      <list-item id="li0005">
       <label>1.</label>
       <p id="p0005">Lopinavir/ritonavir</p>
      </list-item>
      <list-item id="li0010">
       <label>2.</label>
       <p id="p0010">Hydroxychloroquine sulfate</p>
      </list-item>
     </list>
    </td>
    <td>Recruiting</td>
    <td>Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of Korea</td>
   </tr>
   <tr>
    <td>23.</td>
    <td>The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19</td>
    <td>Thalidomide</td>
    <td>Not yet recruiting</td>
    <td>–</td>
   </tr>
   <tr>
    <td>24.</td>
    <td>Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19: A Randomized Control Trial</td>
    <td>Oral</td>
    <td>Not yet recruiting</td>
    <td>Subsai Kongsaengdao, Bangkok, Thailand</td>
   </tr>
   <tr>
    <td>25.</td>
    <td>Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting</td>
    <td>Chloroquine</td>
    <td>Not yet recruiting</td>
    <td>–</td>
   </tr>
   <tr>
    <td>26.</td>
    <td>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</td>
    <td>Favipiravir Combined with Tocilizumab</td>
    <td>Recruiting</td>
    <td>Anhui Medical University Affiliated First Hospital, Hefei, Anhui, China
     <break/>Guiqiang Wang, Beijing, Beijing, China
     <break/>Peking University First Hospital, Beijing, Beijing, China
    </td>
   </tr>
   <tr>
    <td>27.</td>
    <td>Trial of Treatments for COVID-19 in Hospitalized Adults</td>
    <td>1.Remdesivir
     <break/>2.Lopinavir/ritonavir
     <break/>3. Interferon Beta-1A
    </td>
    <td>Not yet recruiting</td>
    <td>–</td>
   </tr>
   <tr>
    <td>28.</td>
    <td>Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization</td>
    <td>Losartan</td>
    <td>Not yet recruiting</td>
    <td>Hennepin County Medical Center, Minneapolis, Minnesota, United States
     <break/>M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States
     <break/>University of Minnesota, Minneapolis, Minnesota, United States
    </td>
   </tr>
   <tr>
    <td>29.</td>
    <td>Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization</td>
    <td>Losartan</td>
    <td>Not yet recruiting</td>
    <td>Hennepin County Medical Center, Minneapolis, Minnesota, United States
     <break/>M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States
     <break/>University of Minnesota, Minneapolis, Minnesota, United States
    </td>
   </tr>
   <tr>
    <td>30.</td>
    <td>Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection</td>
    <td>Ganovo with ritonavir +/-Interferon</td>
    <td>Recruiting</td>
    <td>The Ninth Hospital of Nanchang
     <break/>Nanchang, Jiangxi, China
    </td>
   </tr>
   <tr>
    <td>31.</td>
    <td>Eculizumab (Soliris) in Covid-19 Infected Patients</td>
    <td>Eculizumab</td>
    <td>Initiated</td>
    <td>–</td>
   </tr>
   <tr>
    <td>32.</td>
    <td>Expanded Access Remdesivir (RDV; GS-5734™)</td>
    <td>Remdesivir</td>
    <td>Initiated</td>
    <td>–</td>
   </tr>
   <tr>
    <td>33.</td>
    <td>Norwegian Coronavirus Disease 2019 Study</td>
    <td>Hydroxychloroquine Sulfate</td>
    <td>Not yet recruiting</td>
    <td>–</td>
   </tr>
   <tr>
    <td>34.</td>
    <td>Post-exposure Prophylaxis for SARS-Coronavirus-2</td>
    <td>Hydroxychloroquine</td>
    <td>Recruiting</td>
    <td>University of Minnesota, Minneapolis, Minnesota, United States</td>
   </tr>
   <tr>
    <td>35.</td>
    <td>The efficacy and safety of pirfenidone capsules in the treatment of severe new coronavirus pneumonia (COVID-19)</td>
    <td>Pirfenidone</td>
    <td>–</td>
    <td>Third Xiangya Hospital of Central South University</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>The table represents a list of selected clinical trials for the amelioration of COVID–19 specific drugs and vaccines.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
